Abby Bronson

Title: Vice President, Patient Advocacy & External Innovation

Organization: Edgewise Therapeutics

Bio: Abby Bronson has served as our Vice President of Patient Advocacy and External Innovation since 2020. Ms. Bronson is a leader within the rare disease space and over her career has managed critical alliances and partnerships with academia, biopharmaceutical companies, National Institutes of Health (NIH)/federal programs, patient groups and other stakeholders. Most recently she worked at PPMD as Senior Vice President of Research Strategy where she led the Research Portfolio and built strong relationships with Duchenne academic and clinical researchers, industry and regulators to help incorporate the patient voice and improve drug development success in DMD. Prior to this, Ms. Bronson was at the NIH’s Center for Advancing Translational Sciences, Division of Clinical Innovation where she was Director of Operations for the Clinical and Translational Science Awards Program. Additionally, Ms. Bronson held positions at Children's National Medical Center, where she managed the global development and execution of key translational and drug development initiatives in select rare diseases, focusing on Duchenne at the Research Center for Genetic Medicine; MedImmune (acquired by Astra-Zeneca), where she led marketing initiatives for Synagis (palivizumab) for RSV disease; Medtronic where she managed global product marketing for select medical devices; and Ciba-Geneva Pharmaceuticals (acquired by Novartis) where she was responsible for managing relationships with major managed care organizations and led sales and marketing initiatives for their cardiovascular franchise. Ms. Bronson received her M.B.A from The Wharton School, University of Pennsylvania and B.A. degree from the University of Vermont.

2023 FUTURES: Preserving Muscle Sessions

A brief primer on the muscle preservation and anti-inflammatory treatment approach to Duchenne, and updates from relevant companies in the space. These presentations will be followed by a moderated Q&A opportunity.

Abby Bronson

Vice President, Patient Advocacy & External Innovation

Edgewise Therapeutics

Robert Halter, PharmD

Field Medical Director, South/Southwest Santhera Pharmaceuticals

Karyn Koladicz, MD

Executive Medical Director for Medical Affairs, Neurology PTC Therapeutics

Linda Marbán , PhD

President, CEO and Director Capricor Therapeutics

Beyond Dystrophin Panel

This conference session provides insight and updates from companies whose therapies target critical aspects of the Duchenne disease process that occur alongside reductions in dystrophin.

Abby Bronson

Vice President, Patient Advocacy & External Innovation

Edgewise Therapeutics

Mindy Cameron

Patient Advocacy Lead

Santhera Pharmaceuticals

Matthew Klein, M.D., M.S., FACS

Chief Operating Officer

PTC Therapeutics

Daniel Paulson, MD

Vice President of Clinical Development

Capricor Therapeutics

Han Phan, MD

Director

Rare Disease Research, LLC

Más allá de la distrofina

Esta sesión de la conferencia brinda información sobre las terapias emergentes más allá de la restauración de la distrofina, así como actualizaciones/anuncios de las empresas en este espacio.

Han Phan, MD

Director

Rare Disease Research, LLC

Mindy Cameron

Patient Advocacy Lead

Santhera Pharmaceuticals

Matthew Klein, M.D., M.S., FACS

Chief Operating Officer

PTC Therapeutics

Abby Bronson

Vice President, Patient Advocacy & External Innovation

Edgewise Therapeutics

Daniel Paulson, MD

Vice President of Clinical Development

Capricor Therapeutics